←
Mohamed Mohideen1,865 posts
Mohamed Mohideen avatar

Mohamed Mohideen

@rifdeen

Physician Academic, Emeritus Professor in Medicine, incurable technophile

◷ Joined November 2011▧ 123 Photos and videos
William A. Wallace, Ph.D. avatar
⟳ Mohamed Mohideen retweeted
William A. Wallace, Ph.D.@WilliamWallace·Nov 8

A normal fasting glucose is often read as an all-clear for metabolic health, but it can stay in a reassuring range for years while insulin sensitivity is falling. In the Whitehall II study, researchers followed 6,538 British civil servants without diabetes for a median of almost ten years. During that time, 505 developed type 2 diabetes, and the researchers reconstructed how their blood measures had changed over as many as 13 years before diagnosis. In the people who went on to develop diabetes, insulin sensitivity fell steeply over the five years before diagnosis. Fasting glucose rose only slowly at first and then climbed sharply over the final three years, moving from just above the normal range to above the threshold used to diagnose diabetes. The pancreas's insulin output, estimated from blood tests, rose between four and three years before diagnosis, as if compensating, and then declined. That pattern helps explain why glucose can look fine for a long time. As the body responds less to insulin, extra insulin can keep glucose in check, and fasting glucose tends to rise once that compensation starts to fail. A normal result is reassuring, but it does not rule out insulin resistance. The study population was 71% male and 91% white, and it was an occupational cohort, so the pattern may unfold differently in other groups. The measures of insulin sensitivity and output were estimates rather than gold-standard tests. The study was also observational. It describes how these changes typically unfolded, but it did not test whether measuring insulin earlier improves outcomes. Tabák et al., The Lancet, 2009.

Post attachment
William A. Wallace, Ph.D. avatar
⟳ Mohamed Mohideen retweeted
William A. Wallace, Ph.D.@WilliamWallace·Nov 6

The same meal can raise blood sugar very differently depending on the order you eat it. In a crossover trial of 33 young women wearing continuous glucose monitors, eating vegetables, then protein, then carbohydrate lowered the early rise, the peak, and the overall swing compared with carbohydrate first. An earlier crossover trial in 18 healthy adults found about 41% less glucose exposure and about 32% less insulin exposure over two hours when vegetables and protein came first, with the same foods and calories. These were small, short-term studies in healthy adults, not proof of weight loss or diabetes prevention.

Post attachment
Mohamed Mohideen avatar
Mohamed Mohideen@rifdeen·Sep 30

The future

🚨 الباحثون أثبتوا رسمياً أن الذكاء الاصطناعي أعدم كل سبب لوجود الجامعات! تجربة حاسمة من جامعة "هارفارد" تتسبب في انهيار فقاعة التعليم العالي للأبد! 🎓💥🧠 ​جامعة Harvard أوجدت تجربة صدمت الوسط الأكاديمي بأكمله بعد مقارنة طلابها بأحدث المعلمين الذكيين (AI Tutor): ​أخذوا 194 طالباً وقسموهم لـ مجموعتين لتعلم المادة نفسها: • المجموعة الأولى: تعلّمت الفيزياء في أرقى قاعات هارفارد التفاعلية مع أفضل الدكاترة والخبراء (التجربة الكاملة لجامعة بـ 60,000$ سنوياً!). • المجموعة الثانية: ذهبت للمنزل وتعلّمت المادة نفسها باستخدام AI Tutor فقط! ​النتيجة؟ الـ AI لم يكتفِ بالفوز.. بل سحق المنظومة! 👇 ​• ضعف الاستيعاب: الطلاب الذين استخدموا الـ AI تعلموا أكثر من ضعفي (2x) ما تعلمه طلاب قاعات هارفارد النخبوية! • تفوق ساحق: حققوا نتائج أعلى بنسبة 30% في الاختبار النهائي! • زمن أقل: وأنجزوا كل ذلك في وقت أقصر بكثير! ​💡 كيف حدث هذا السحر؟ الـ AI لم يعطِ الطلاب إجابات جاهزة.. بل استخدم أساليب تربوية صارمة؛ كان يسأل، يوجه، ويجبر الطالب على التفكير العميق، مع تقديم توجيه فردي خالي من الأخطاء في اللحظة التي يتعثر فيها الطالب بنفسه! وهذا مستوى مستحيل رياضياً توفيره داخل قاعة محاضرة بها عشرات الطلاب. ​الخلاصة المدوية: طوال ألف عام، كانت الجامعة هي المكان الوحيد للحصول على تعليم نخبي.. اليوم، أصبحت هي العائق والعقبة! ​عندما يستطيع برنامج بسيط مضاعفة سرعة تعلمك بكسر بسيط من التكلفة.. على ماذا يدفع الطلاب ديوناً تستمر لعقود؟ 🤯 ​احفظ التغريدة فوراً لتعيد التفكير في مستقبل التعليم، وشاركها مع كل طالب وأب ومطور! 🔖🧵👇

Post attachment
Mario Nawfal avatar
⟳ Mohamed Mohideen retweeted
Mario Nawfal@MarioNawfal·Sep 23

🇺🇸 An AI was reading raw DNA when it spotted a pattern scientists apparently hadn't noticed before. Around 950 Claude agents spent 21 hours combing through more than 200,000 enzymes until one spotted an odd repeating pattern inside a virus that infects bacteria. Lab tests found it's part of a previously uncharacterized enzyme system that resembles CRISPR, the system scientists turned into a powerful tool for editing DNA. What this new system actually does is still a mystery. The scientists basically gave Claude the first prompt and handled the lab work, while CRISPR pioneer Feng Zhang called the find “genuinely intriguing.” CRISPR itself started with someone noticing a strange repeating pattern in bacterial DNA. This time, the one who noticed was an AI. Source: Anthropic / Writer: Daniyal

Post attachmentPost attachmentPost attachmentPost attachment
William A. Wallace, Ph.D. avatar
⟳ Mohamed Mohideen retweeted
William A. Wallace, Ph.D.@WilliamWallace·Sep 10

Apple cider vinegar has built an entire wellness category on a real effect attributed to the wrong ingredient. The glucose-lowering data is genuine. The apple has nothing to do with it. The acetic acid is what does the work, and any vinegar at the same concentration produces the same effect. The original Johnston et al. study (Diabetes Care 2004) gave insulin-resistant and type 2 diabetic adults a vinegar drink before a meal containing 87 g of carbohydrates and saw postprandial glucose drop 64% in the insulin-resistant group and 19% in the diabetic group. The sample was small (n=29 crossover) but the effect size was large. Ostman et al. (Eur J Clin Nutr 2005) ran the dose-response experiment. They served white bread with vinegar at three levels of acetic acid (18, 23, and 28 mmol) to healthy adults. Both glucose and insulin responses fell as acetic acid content rose. The effect tracked the acetic acid content, not the vinegar volume. The 2017 meta-analysis by Shishehbor et al. (Diabetes Res Clin Pract) pooled the controlled trials. Vinegar consumption with a meal reduced postprandial glucose AUC (SMD -0.60, 95% CI -1.08 to -0.11) and insulin AUC (SMD -1.30, 95% CI -1.98 to -0.62). The effect is consistent and the magnitude is meaningful. The mechanism is well-characterized. Liljeberg and Bjorck (Eur J Clin Nutr 1998) showed in healthy adults that adding vinegar to a starch meal delayed gastric emptying and that this delay tracked with the improved glycemic response. Slower emptying means slower carbohydrate delivery to the small intestine, which flattens the glucose curve. A secondary mechanism is inhibition of disaccharidase activity by acetate at the brush border. Neither depends on the source of the acetic acid. The longer-term data is much weaker. Johnston et al. (Food Funct 2020) ran an 8-week trial of daily red wine vinegar in 45 adults at risk for metabolic complications. Fasting glucose and insulin sensitivity improved significantly, but body mass, waist circumference, and visceral fat did not change. The viral "ACV for weight loss" claim has thin support. Two practical implications. First, if you want the postprandial effect, you need liquid vinegar at roughly 1 to 2 tablespoons. The dose has to deliver around 750 to 1500 mg of acetic acid. White, red wine, rice, and apple cider vinegars all work. Second, the gummies and tablets are a problem. Johnston et al. (J Nutr Metab 2022) tested commercial vinegar tablets head-to-head against liquid vinegar and found the tablets failed to lower postprandial glucose to the same degree. The mother, the fermentation, the apple, the brand. None of it is the active ingredient. The acetic acid is. Johnston et al., Diabetes Care 2004 Liljeberg and Bjorck, Eur J Clin Nutr 1998 Ostman et al., Eur J Clin Nutr 2005 Shishehbor et al., Diabetes Res Clin Pract 2017 Johnston et al., Food Funct 2020 Johnston et al., J Nutr Metab 2022

Post attachment
Anthropic avatar
⟳ Mohamed Mohideen retweeted
Anthropic@AnthropicAI·Sep 10

We're publishing our most detailed threat intelligence report to date. It covers how people tried to misuse Claude—for cyberattacks, influence operations, surveillance, biology, and building weapons—and how we found and stopped them. We disrupted every operation in the report, and used the lessons from them to strengthen our safeguards. Where appropriate, we also shared what we found with authorities and other AI companies. These cases are not typical: we’re highlighting some of the most sophisticated misuse we’ve seen. But they’re especially important to discuss, because they show us where AI misuse is headed, where our safeguards work, and where they need to improve. We’re publishing this report so others can spot the same activity on their own platforms, and so we can give the public a clearer view of how emerging threats develop. Read the report: anthropic.com/threat-intelli…

TCTMD avatar
⟳ Mohamed Mohideen retweeted
TCTMD@TCTMD·Sep 9

FDA Clears First AI-ECG Model for Acute MI Detection dlvr.it/TVPfTC

Post attachment
Medscape avatar
⟳ Mohamed Mohideen retweeted
Medscape@Medscape·Sep 10

Among adults with overweight or obesity, tirzepatide was associated with greater weight reduction and glycemic improvement than semaglutide but was also linked to a higher risk for serious adverse events, according to a meta-analysis of head-to-head studies. "Among adults with overweight or obesity, tirzepatide is associated with greater weight reduction and modestly greater glycaemic improvement compared with semaglutide, although these benefits may be accompanied by a higher risk of serious adverse events. These findings highlight the need to balance efficacy and tolerability when selecting incretin-based therapies," the authors wrote. mdsc.pe/4xPMvqt

Post attachment
PBS News avatar
⟳ Mohamed Mohideen retweeted
PBS News@NewsHour·Sep 9

Concerns about the risks of AI and whether the companies building it are doing enough to keep it safe erupted across the tech world, following the public resignation of an Anthropic researcher. Jacob Coxon, who previously worked at OpenAI, wrote in a post that the industry understands the potential risks but is moving ahead anyway. @GeoffRBennett speaks to @AmrithRamkumar for more.

5:47
Medscape avatar
⟳ Mohamed Mohideen retweeted
Medscape@Medscape·Sep 6

Beyond the library of textbooks runs another shelf of medicine — one made up of novels, essays, and memoirs that explore the field not through knowledge, but through lived experience. These are books about care when cure is no longer possible, about error and accountability, about bodies that fail and minds that endure, about limits and the many ways people push against them. For many physicians, these works prove more formative than entire courses. We've gathered 10 titles every doctor should read at least once - tap the link full list: mdsc.pe/3Uy39Mr

Post attachment
Dr Ihab Suliman avatar
⟳ Mohamed Mohideen retweeted
Dr Ihab Suliman@IhabFathiSulima·Sep 1

🚨 ESC 2026 قرر أن يغيّر القواعد… مرة أخرى 😂🫀 10 رسائل جعلت أطباء القلب يعيدون التفكير في أشياء كانوا يعتقدون أنها “محسومة”: 1️⃣ HFmrEF؟ شكرًا لخدماتك! 👋 الـ EF لم يعد ذلك الرقم المقدس الذي نبني عليه كل شيء. 2️⃣ MRA يقول للـ EF: أنا لا أهتم بك! 😎 العلاج يتوسع عبر طيف قصور القلب… والـ guidelines تزداد سماكة سنة بعد سنة. 3️⃣ SINGLE-AF: كنا نقول: “الخطورة متوسطة… نراقب.” الآن قد تصبح الإجابة: أين الـ DOAC؟ 🩸 4️⃣ Severe TR: قديمًا: Lasix ➕ المزيد من Lasix ➕ دعاء. 🙏😂 ESC 2026: ربما حان وقت إصلاح الصمام فعليًا. 5️⃣ Syncope غير مفسر؟ لا تقل له: “تحاليلك سليمة، اشرب ماء وارجع للبيت.” 😅 ASPIRED يقول: راقب النظم فترة أطول… قد يكون القلب يخفي المفاجأة. ⚡ 6️⃣ Intermediate-high risk PE: الـ anticoagulation ينظر بقلق إلى catheter-directed therapy وهي تقترب منه. 👀🫁 7️⃣ Cardiac arrest بدون STEMI؟ الـ Cath Lab ليس غرفة الطوارئ لكل شيء! 😂 DISCO: القسطرة الفورية للجميع لم تحسن البقاء. 8️⃣ المريض عمره 75 سنة؟ لا تقل: “خلاص، ما عاد يحتاج primary prevention.” STAREE: الستاتين ما زال في اللعبة. 💊 9️⃣ AF ablation: نعم، يقلل الرجفان… لكن دراسة sham جعلتنا نسأل السؤال المحرج: كم من تحسن الأعراض كان بسبب الـ ablation نفسه؟ 😳 🔟 وحتى MI لم يسلم! بعد سنوات من حفظ Type 1 و2 و4 و5… ESC يقول لك: استعد لتصنيف أبسط. 😂 🔥 الخلاصة: إذا كنت طبيب قلب وحفظت الـ guidelines بالكامل… لا تقلق. سيتم تغييرها قريبًا. 😅🫀 #ESC2026 #Cardiology #HeartFailure #AF #MedicalHumor #CardiologyUpdates

Pablo Corral MD avatar
⟳ Mohamed Mohideen retweeted
Pablo Corral MD@drpablocorral·Jul 19

👉Moderate-Intensity Statin + Ezetimibe: The Sweet Spot? ☝️A new network meta-analysis including 38 randomized controlled trials and 7,340 patients with coronary heart disease suggests that adding ezetimibe to a moderate-intensity statin may provide lipid lowering comparable to high-intensity statin-based strategies across most lipid parameters. ☝️Key findings 1️⃣ Moderate-intensity statin (MIS) + ezetimibe ranked highest for LDL-C reduction. 2️⃣ LDL-C lowering with MIS + ezetimibe was comparable to high-intensity statin (HIS) + ezetimibe. 3️⃣ MIS + ezetimibe also showed the best overall performance for HDL-C, total cholesterol, non-HDL-C, and ApoB. 4️⃣ HIS + ezetimibe ranked highest for triglyceride reduction, but without a statistically significant advantage over MIS + ezetimibe. 5️⃣ Among moderate-intensity regimens, rosuvastatin + ezetimibe appeared to provide the greatest lipid-lowering efficacy. pdf.pdf ☝️Clinical message 1️⃣ Before automatically escalating to high-intensity statins, consider early combination therapy with ezetimibe. 2️⃣ This strategy may maximize LDL-C lowering while potentially improving tolerability and long-term adherence. 3️⃣ These findings reinforce a principle increasingly supported by contemporary guidelines: “add rather than double.” 👉 Combination therapy beats dose escalation. Adding ezetimibe to a moderate-intensity statin achieves lipid lowering comparable to high-intensity statin strategies across most parameters, reinforcing the principle of “add early, don’t just intensify.” 🔗doi.org/10.1016/j.jacl.2026.… @LipidJournal @nationallipid @society_eas

Post attachment
Eric Topol avatar
⟳ Mohamed Mohideen retweeted
Eric Topol@EricTopol·Jul 18

At least 10% of the population has a significantly elevated Lp(a) above 50 mg/dL (~125 nmol/L), which carries an increased risk of atherosclerotic cardiovascular disease. While we've known that for decades, we've never had a drug to treat it. There are 5 programs in advanced trials (Table below, 3 in phase 3, pivotal, CV outcomes as endpoint). We may see the results for the first drug (pelacarsen) soon, by end August, and FDA approval is expected in 2027. This likely represents a major advance for preventing heart disease, adding to the first oral PCSK9 blocker approved this week.

Post attachment
Michael Weintraub, MD avatar
⟳ Mohamed Mohideen retweeted
Michael Weintraub, MD@MWeintraubMD·Jul 16

🚨 PCSK9 inhibitors are by far the most potent LDL lowering medications available. Their major limitation has been they are injectable medications. Now the FDA just approved the first oral PCSK9 inhibitor. 💊 Lipfendra (enlicitide): once-daily 20 mg tablet approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. ⬇️ LDL-C reduced 56% vs placebo at 24 weeks ⬇️ Significant reductions also seen in non-HDL-C and ApoB 🔬 This is not a monoclonal antibody like evolocumab (Repatha) or alirocumab (Praluent). Enlicitide is a macrocyclic peptide, a different molecular approach to inhibiting the PCSK9-LDL receptor interaction, designed for oral bioavailability. ⚖️ Safety profile diarrhea (7% vs 2%) and dizziness (9% vs 4%) were more common with drug. 🫀 The unanswered question: does it reduce cardiovascular events? The CORALreef Outcomes trial (n=14,500+) is ongoing. nytimes.com/2026/07/16/scien…

Post attachment
Isaac Lamb, MD avatar
⟳ Mohamed Mohideen retweeted
Isaac Lamb, MD@IsaacLamb01·Jul 1

Candesartan: an underutilized tool for migraine prevention? Despite the success of the new generation of CGRP inhibitors, there is still a need for affordable, well-tolerated, and effective migraine preventatives for non-responders and resource-limited settings.